Browse our anti-SNCA (SNCA) Antibodies

Full name:
anti-Synuclein, alpha Antibodies (SNCA)
On www.antibodies-online.com are 739 Synuclein, alpha (SNCA) Antibodies from 40 different suppliers available. Additionally we are shipping SNCA Proteins (74) and SNCA Kits (68) and many more products for this protein. A total of 906 SNCA products are currently listed.
Synonyms:
alphaSYN, LOC619283, MGC64356, NACP, PARK1, PARK4, PD1, snca

All available anti-SNCA Antibodies

Go to our pre-filtered search.

Top referenced anti-SNCA Antibodies

  1. Human Monoclonal SNCA Primary Antibody for EIA, IHC (fro) - ABIN264097 : Trojanowski, Lee: \' of proteins. A comprehensive hypothetical mechanism underlying Alzheimer's disease and other neurodegenerative disorders. in Annals of the New York Academy of Sciences 2001 (PubMed)
    Show all 9 references for 264097

  2. Human Polyclonal SNCA Primary Antibody for EIA, WB - ABIN358993 : Kumru, Santamaria, Tolosa, Valldeoriola, Muñoz, Marti, Iranzo: Rapid eye movement sleep behavior disorder in parkinsonism with parkin mutations. in Annals of neurology 2004 (PubMed)
    Show all 5 references for 358993

  3. Human Polyclonal SNCA Primary Antibody for EIA, IHC (p) - ABIN358988 : Pigullo, De Luca, Barone, Marchese, Bellone, Colosimo, Scaglione, Martinelli, Di Maria, Pizzuti, Abbruzzese, Dallapiccola, Ajmar, Mandich: Mutational analysis of parkin gene by denaturing high-performance liquid chromatography (DHPLC) in essential tremor. in Parkinsonism & related disorders 2004 (PubMed)
    Show all 5 references for 358988

  4. Human Monoclonal SNCA Primary Antibody for EIA, IHC (fro) - ABIN264470 : McLean, Kawamata, Ribich, Hyman: Membrane association and protein conformation of alpha-synuclein in intact neurons. Effect of Parkinson's disease-linked mutations. in The Journal of biological chemistry 2000 (PubMed)
    Show all 3 references for 264470

  5. Human Monoclonal SNCA Primary Antibody for ICC, FACS - ABIN439712 : Huang, Xu, Wu, Zhou: Determining nuclear localization of alpha-synuclein in mouse brains. in Neuroscience 2011 (PubMed)
    Show all 2 references for 439712

  6. Human Polyclonal SNCA Primary Antibody for IHC (p), WB - ABIN390364 : West, Kapatos, OFarrell, Gonzalez-de-Chavez, Chiu, Farrer, Maidment: N-myc regulates parkin expression. in The Journal of biological chemistry 2004 (PubMed)
    Show all 2 references for 390364

  7. Human Polyclonal SNCA Primary Antibody for WB - ABIN390368 : Wang, Denison, Lai, Philips, Montoya, Kock, Schüle, Klein, Shridhar, Roberts, Smith: Parkin gene alterations in hepatocellular carcinoma. in Genes, chromosomes & cancer 2004 (PubMed)
    Show all 2 references for 390368

  8. Human Monoclonal SNCA Primary Antibody for ELISA, WB - ABIN316106 : Herva, Zibaee, Fraser, Barker, Goedert, Spillantini: Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA). in The Journal of biological chemistry 2014 (PubMed)

  9. Human Polyclonal SNCA Primary Antibody for ELISA, WB - ABIN1531986 : Campion, Martin, Heilig, Charbonnier, Moreau, Flaman, Petit, Hannequin, Brice, Frebourg: The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. in Genomics 1995 (PubMed)

  10. Cow (Bovine) Polyclonal SNCA Primary Antibody for WB - ABIN2775366 : Wu, Kim, Fela, Baum: Characterization of conformational and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: implication for aggregation. in Journal of molecular biology 2008 (PubMed)

More Antibodies against SNCA Interaction Partners

Xenopus laevis Synuclein, alpha (SNCA) interaction partners

  1. study examined the spatial and temporal expression patterns of three synuclein genes (snca, sncbb, sncg (show SNCG Antibodies)) during embryogenesis

Mouse (Murine) Synuclein, alpha (SNCA) interaction partners

  1. Data suggest that endocytosis is the principal mechanism by which proteopathic alpha-synuclein aggregates are internalized in primary hippocampal neurons in culture; aggregates are rapidly trafficked along endosomal/lysosomal pathway, where most of the material remains for days as proposed in neurodegenerative synucleinopathies.

  2. LRRK2 (show LRRK2 Antibodies) negatively regulates the clearance of alphaSYN accompanied by down-regulation of the endocytosis pathway; LRRK2 (show LRRK2 Antibodies) in microglia may function as the offending molecule responsible for neurodegeneration, in terms of down-regulation of alphaSYN clearance.

  3. sideroflexin 3 (SFXN3 (show SFXN3 Antibodies)) was found to be a mitochondrial protein (show COX6B2 Antibodies) localized to the inner mitochondrial membrane.

  4. The ability of monomeric alpha-synuclein to enhance ATP synthase efficiency under physiological conditions may be of importance when alpha-synuclein undergoes the misfolding and aggregation

  5. Rab7 (show RAB7A Antibodies) accumulated in GCase (show GBA Antibodies) deficient cells, supporting the notion that lysosomal recycling is impaired. Since recombinant GCase (show GBA Antibodies) can reverse ALR (show GFER Antibodies) impairment, we anticipate that strategies to restore GCase (show GBA Antibodies) activity in the brains of both sporadic patients with PD and those with GBA1 (show GBA Antibodies) mutations will improve autophagy lysosomal pathway, preventing the accumulation of a-synuclein and spread of pathology.

  6. Study showed that apoptosis is an important form of cellular degeneration in lipopolysaccharide (LPS (show TLR4 Antibodies)-sensitized hypoxic-ischemic (HI) injury in the immature brain. Loss of PINK1 (show PINK1 Antibodies) can protect the immature brain against cell apoptosis induced by LPS (show TLR4 Antibodies)-sensitized HI injury. Moreover, alpha-Syn plays a neuroprotective role in LPS (show TLR4 Antibodies)-sensitized HI brain damage in PINK1 (show PINK1 Antibodies)-knockout neonatal mice

  7. Genetic manipulation of sirtuin 2 (show SIRT2 Antibodies) levels in vitro and in vivo modulates the levels of alpha-synuclein acetylation, its aggregation, and autophagy.

  8. These results indicate that fragmented amyloid-like aggregates of short alpha-syn fibrils are the key pathogenic seeds that trigger prion (show PRNP Antibodies)-like conversion.

  9. In summary, we have combined multiple data sets to identify transcripts, which are strong candidates for being phenotypic modifiers, and demonstrated SNCA is a modifier of pathology in motor neuron disease.

  10. In alpha-synuclein knock-out mice there was a decrease in neuronal glucose metabolism in cerebral cortex gray matter.

Human Synuclein, alpha (SNCA) interaction partners

  1. Study suggests histones as prime candidates for one of the nuclear proaggregant factors involved in the formation of transmissible alpha-synuclein aggregates during neuron apoptosis.

  2. Study provides evidence that phosphorylated alpha-synuclein deposition is present in dermal nerve fibers in a subgroup of patients suffering from REM (show REM1 Antibodies) sleep behavior disorder, presumably representing prodromal Parkinson's disease.

  3. This review describes the major findings supporting the occurrence of alpha-synuclein pathology propagation in Parkinson's disease and discusses how this phenomenon could induce or contribute to synaptic injury and degeneration. [Review]

  4. This review evaluated major classes of molecular chaperones and their mechanisms relevant for preventing protein aggregation, specific case of alpha-synuclein aggregation. [review]

  5. Data suggest that endocytosis is the principal mechanism by which proteopathic alpha-synuclein aggregates are internalized in primary hippocampal neurons in culture; aggregates are rapidly trafficked along endosomal/lysosomal pathway, where most of the material remains for days as proposed in neurodegenerative synucleinopathies.

  6. Data suggest that endocytosis and lysosomal processing of proteopathic alpha-synuclein aggregates in neurons are consistent with models of neurodegeneration in synucleinopathies. [EDITORIAL]

  7. These results indicate that LRRK2 (show LRRK2 Antibodies) and alpha-synuclein participate in the dysregulation of CADPS2 (show CADPS2 Antibodies) by altering transcription and support the hypothesis that synaptic dysfunctions, through different mechanisms, might contribute to the neuronal defects of diseases such as Parkinson's disease.

  8. Increasing evidence supports that small alpha-synuclein aggregates or oligomers may be the real culprit, causing deficits in neurotransmission and neurogenesis in the hippocampus and related brain regions, which constitute the major mechanism for the hippocampal dysfunctions and associated neuropsychiatric manifestations in synucleinopathies. [alpha-synuclein]

  9. Most anti-PD1 (show PDCD1 Antibodies)-related adrenal insufficiency cases involved an isolated ACTH (show POMC Antibodies) deficiency. Eosinophilia may be an early indicator before the onset of symptoms.

  10. Significantly higher transcript expression levels of PD1 (show PDCD1 Antibodies) were found in tumor tissue, whilst a general increase in PDL1 (show CD274 Antibodies) expression was found in tumor tissues, although this did not reach statistical significance. Our study demonstrates higher levels of expression of PDL1 (show CD274 Antibodies) are associated with favorable clinical outcome.

Cow (Bovine) Synuclein, alpha (SNCA) interaction partners

  1. analysis of membrane curvature sensing by amphipathic helices using alpha-synuclein and annexin B12 (show TNFAIP1 Antibodies) [ANXB12]

  2. Immunocytochemistry shows alpha synuclein localized to the Golgi apparatus and vesicles of bovine adrenal medullary chromaffin cells, consistent with its putative role in vesicular function within synapses.

SNCA Antigen Profile

Antigen Summary

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene.

Alternative names and synonyms associated with SNCA

  • synuclein, alpha (snca) antibody
  • alpha-synuclein (LOC619283) antibody
  • alpha-synuclein (LOC100359228) antibody
  • synuclein, alpha (Snca) antibody
  • synuclein, alpha (non A4 component of amyloid precursor) (SNCA) antibody
  • synuclein, alpha (non A4 component of amyloid precursor) (Snca) antibody
  • alphaSYN antibody
  • LOC619283 antibody
  • MGC64356 antibody
  • NACP antibody
  • PARK1 antibody
  • PARK4 antibody
  • PD1 antibody
  • snca antibody

Protein level used designations for anti-Synuclein, alpha (SNCA) Antibodies

synuclein, alpha , alpha-synuclein , alpha SYN , non-A beta component of AD amyloid , non-A4 component of amyloid , non A-beta component of AD amyloid , synuclein alpha-140 , alpha synuclein

GENE ID SPECIES
380315 Xenopus laevis
619283 Takifugu rubripes
100359228 Oryctolagus cuniculus
20617 Mus musculus
6622 Homo sapiens
29219 Rattus norvegicus
641350 Sus scrofa
282857 Bos taurus
395393 Gallus gallus
100294604 Ovis aries
Selected quality suppliers for anti-SNCA (SNCA) Antibodies
Did you look for something else?